Drug intelligence / Profile preview

HN0141

Development stage: Unknown
Lead developer: Phaeno Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

HN0141 is a recombinant monoclonal antibody developed by Huinuo Biopharmaceutical Technology (Hangzhou) Co., Ltd. for the prevention and treatment of human cytomegalovirus (HCMV) infection. HCMV is a significant cause of morbidity in immunocompromised individuals, such as hematopoietic stem cell or solid organ transplant recipients. HN0141 is designed to neutralize the virus by binding to essential viral surface glycoproteins, thereby blocking viral entry into host cells. As of late 2023, the candidate is in Phase 1 clinical development in China to evaluate its safety, tolerability, and pharmacokinetic profile in healthy volunteers.

Targets

pUL56 (Human cytomegalovirus DNA terminase complex subunit UL56)

Beyond the preview

Go deeper on HN0141.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HN0141.

Explore the full profile